Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$118.50 USD

118.50
1,155,790

-2.39 (-1.98%)

Updated Sep 3, 2024 04:00 PM ET

Pre-Market: $118.38 -0.12 (-0.10%) 9:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Debanjana Dey headshot

Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on

by Debanjana Dey

Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.

Deciphera (DCPH) Begins Dosing in Study on Cancer Candidate

by Zacks Equity Research

Deciphera (DCPH) doses the first patient in a phase I study evaluating its ULK kinase inhibitor, DCC-3116, for treating advanced/metastatic tumors driven by mutations in RAS/RAF genes.

Gilead's (GILD) Kite Announces Positive Data on Yescarta

by Zacks Equity Research

Gilead (GILD) announces results from the ZUMA-7 study on Yescarta and completes submission of application to the FDA seeking approval of lenacapavir.

Incyte's (INCY) Lymphoma Drug Obtains Positive CHMP Opinion

by Zacks Equity Research

Incyte (INCY) and MorphoSys (MOR) receive positive CHMP opinion for tafasitamab in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Lilly's (LLY) AD Candidate Gets Breakthrough Therapy Status

by Zacks Equity Research

Eli Lilly (LLY) is developing donanemab in a phase III study and plans to file a regulatory application seeking accelerated approval for the candidate as a treatment for AD in 2021.

Roche's (RHHBY) BLA for PDS With Ranibizumab Accepted by FDA

by Zacks Equity Research

The FDA accepts and grants Priority Review to Roche's (RHHBY) application for Port Delivery System with ranibizumab for the treatment of nAMD.

Sanofi's (SNY) Aubagio Gets EU Nod for MS in Pediatric Patients

by Zacks Equity Research

The European Commission approves Sanofi's (SNY) Aubagio for the treatment of pediatric patients aged 10 to 17 years with relapsing-remitting multiple sclerosis.

Biogen (BIIB) Ends Development of Anti-Tau Alzheimer's Drug

by Zacks Equity Research

Biogen (BIIB) ends development of investigational anti-tau antibody, gosuranemab for treating Alzheimer's disease after the phase II TANGO study showed no benefit to patients.

Incyte (INCY) Faces Delay in Approval of Atopic Dermatitis Cream

by Zacks Equity Research

Incyte's (INCY) NDA review for ruxolitinib cream for the treatment of atopic dermatitis gets extended.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approval for NVO, PFE Products & Other Updates

by Kinjel Shah

FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.

Incyte's (INCY) sNDA Review for Jakafi in GVHD Gets Extended

by Zacks Equity Research

Incyte's (INCY) sNDA review of Jakafi for the indication of steroid-refractory chronic GVHD gets extended by three months.

Biogen (BIIB) Up as FDA Approves Alzheimer'S Drug Aducanumab

by Zacks Equity Research

FDA approves Biogen's (BIIB) Aduhelm (aducanumab), making it the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.

Kinjel Shah headshot

3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug

by Kinjel Shah

FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.

Novartis (NVS) Posts Positive Data on Kidney Disease Candidate

by Zacks Equity Research

Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.

Novartis (NVS) Announces Data on Radioligand Therapy at ASCO

by Zacks Equity Research

Novartis (NVS) posts results from a late-stage study on radioligand therapy at the 2021 ASCO.

AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Maintenance Study

by Zacks Equity Research

AbbVie (ABBV) is focusing on label expansion of Skyrizi beyond plaque psoriasis. The drug achieves endoscopic response and clinical remission as maintenance treatment for Crohn's disease study.

Amgen's (AMGN) KRAS Inhibitor Gets FDA Nod for Lung Cancer

by Zacks Equity Research

FDA approval of Amgen's (AMGN) Lumakras for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer is based on positive data from the phase II CodeBreaK 100 study.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Cancer Drug Gets FDA Nod, PFE, GSK, SNY Begin New Studies

by Kinjel Shah

Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine candidate enters phase III. FDA approves J&J's (JNJ) Rybrevant (amivantamab) for a rare lung cancer

Novartis (NVS) & Molecular Partners Initiate Study for COVID-19

by Zacks Equity Research

Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.

PTC Therapeutics' (PTCT) PTC923 Gets Orphan Drug Tag in US & EU

by Zacks Equity Research

The FDA and the European Commission bestow Orphan Drug status to PTC Therapeutics' (PTCT) PTC923 for the treatment of hyperphenylalaninemia.

J&J's (JNJ) Multiple Sclerosis Drug Ponvory Gets EU Approval

by Zacks Equity Research

J&J's (JNJ) oral multiple sclerosis drug, Ponvory, receives approval in Europe after demonstrating superior efficacy in reducing annual relapses compared to Sanofi's Aubagio in clinical studies.

Kinjel Shah headshot

Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal

by Kinjel Shah

Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints

Incyte (INCY) Announces Positive Results From Vitiligo Study

by Zacks Equity Research

Incyte (INCY) announces positive data from phase III studies on ruxolitinib cream for the treatment of vitiligo.

Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss

by Zacks Equity Research

Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.

Incyte (INCY) Q1 Earnings Beat, Sales Miss on Soft Jakafi

by Zacks Equity Research

Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.